Joel Greenblatt's IBRX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 175,564 shares of ImmunityBio, Inc. (IBRX) worth $1.54 M, representing 0.00% of the portfolio. First purchased in 2023-Q4, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in IBRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2026, adding 163,427 shares. Largest reduction occurred in Q2 2025, reducing 28,781 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's ImmunityBio (IBRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly ImmunityBio (IBRX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +163,427 | Add 1346.52% | 175,564 | $8.76 |
| Q1 2026 | +12,137 | New Buy | 12,137 | $7.67 |
| Q3 2025 | -16,224 | Sold Out | 0 | $0.00 |
| Q2 2025 | -28,781 | Reduce 63.95% | 16,224 | $2.64 |
| Q1 2025 | +45,005 | New Buy | 45,005 | $3.01 |
| Q3 2024 | -14,594 | Sold Out | 0 | $0.00 |
| Q2 2024 | -17,932 | Reduce 55.13% | 14,594 | $6.32 |
| Q1 2024 | +21,738 | Add 201.50% | 32,526 | $5.37 |
| Q4 2023 | +10,788 | New Buy | 10,788 | $5.02 |
Joel Greenblatt's ImmunityBio Investment FAQs
Joel Greenblatt first purchased ImmunityBio, Inc. (IBRX) in Q4 2023, acquiring 10,788 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held ImmunityBio, Inc. (IBRX) for 9 quarters since Q4 2023.
Joel Greenblatt's largest addition to ImmunityBio, Inc. (IBRX) was in Q2 2026, adding 175,564 shares worth $1.54 M.
According to the latest 13F filing for Q2 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 175,564 shares of ImmunityBio, Inc. (IBRX), valued at approximately $1.54 M.
As of the Q2 2026 filing, ImmunityBio, Inc. (IBRX) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in ImmunityBio, Inc. (IBRX) was 175,564 shares, as reported at the end of Q2 2026.